The Chinese Familial Alzheimer's Network — CFAN  

Alzheimer Disease Clinical Trial

Official title: A Multi-center Longitudinal Cohort Study of Familial Alzheimer's Disease in China

Status Recruiting

Clinical Trial Summary

This research will establish and continuously improve the FAD research network in conjunction with multi-center institutions nationwide. By collecting information on the family's demography, genetics, neuropsychology, neuroimaging, biomarkers and other information, we can understand the current FAD population in China, clarify the genetic characteristics, pathogenesis, disease characteristics and diagnosis and treatment status of AD in China; which will lay the foundation for ameliorating clinical diagnosis and treatment, establishing a Chinese FAD clinical database and an international cooperative research platform.

1. To set up a multi-center, nationwide FAD research network and database platform in China

2. To clarify the epidemiological characteristics of FAD in China.

3. To clarify the genetic characteristics of FAD in China.

4. To clarify the clinical characteristics and disease development laws of FAD.

5. To discover and verify the early diagnosis biomarkers of AD.

6. To establish a genetic counseling model.

Clinical Trial Description

1. The network and database include ADAD cohort of the known mutations of PSEN1, PSEN2 and APP (mutation carriers and noncarriers; pre-symptomatic and symptomatic) and unknown mutations cohort.

2. Conduct a comprehensive FAD epidemiological survey in China to clarify the impact of different nationalities, regions, gender, age, living environment (rural/urban), education level, etc. on the occurrence and development of the disease.

3. This project is to discover new FAD mutation sites，pathogenic genes, to protective genes, to explore the pathogenic and protective mechanism, to analyze the disease development laws of families with different sizes of FAD in China, and to clarify the frequency distribution of mutant genes in the Chinese FAD population.

4. The project will collect and regularly follow-up the samples (blood, urine and saliva etc.) and data (neuropsychology, imaging etc.) in the cohort. Emphasis is placed on the occurrence and development of asymptomatic mutant gene carriers from asymptomatic to symptomatic periods.

5. In the FAD family cohort, we will screen high-sensitivity and high-specificity body fluid markers suitable for Chinese people, verify in the SAD cohort, and establish a prediction model of body fluid markers for AD occurrence and disease progression; use structural MRI, dual tracer 18F-FDG PET and 11C-PIB PET multimodal imaging technology, dynamically monitor the dynamic evolution of imaging biomarkers such as brain structure, glucose metabolism and Aβ deposition at various stages of AD progression.

6. We will combine with the genetic characteristics of Chinese FAD to analyze the impact of lifestyle, physical exercise, nootropic drugs, cognitive training, etc. on the disease progression of FAD patients or asymptomatic mutant gene carriers, to establish a genetic counseling model. ;

Related Conditions & MeSH terms

• Alzheimer Disease
• Familial Alzheimer Disease (FAD)

• NCT number: NCT03657732
• Study type: Observational [Patient Registry]
• Source: Capital Medical University
• Contact: Jianping Jia, Doctor
• Phone: +8610-83199449
• Email: jiajp@vip.126.com
• Status: Recruiting
• Start date: January 10, 2005
• Completion date: January 1, 2038